Phase 4 Sleep Disorders Trial, Recruiting NCT06380491 Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Condition: Sleep Disorders
Back to Sleep Disorders

Phase 4 Sleep Disorders Trial, Recruiting

NCT06380491
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Obstructive Sleep Apnea (a condition where breathing repeatedly stops during sleep) confirmed by an overnight sleep study
  • People whose blood pressure does not drop as expected during sleep, as measured by a device worn to monitor blood pressure over 24 hours

Who may not be able to join:

  • People who are currently taking medication for sleep problems or psychiatric (mental health) conditions
  • People who currently use a CPAP or BiPAP machine (a breathing device worn during sleep to keep the airway open)
  • People who have a neurological (brain or nervous system) or psychiatric (mental health) condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Matilde Valencia-Flores, PhD, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)

Phone: (+52 55) 54870900

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Registry
ClinicalTrials.gov
Start date
22 June 2023
Est. completion
22 December 2027

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Melatonin at a dose of 3 mg before sleep time, after a period of 30 days changes the time awake after sleep onset (WASO), and recovers the dipper pattern of blood pressure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov